Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Software Enhancements to the Respironics BiPAP Auto Servo Ventilation (AutoSV) Device

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Pre-Study Inclusion Criteria:~* Age 21-80~* Ability to provide consent~* Documentation of medical stability by investigator~Enrollment Inclusion Criteria:~• Participants who, during the ambulatory polysomnography (PSG) study (Stardust), or in lab Diagnostic PSG demonstrated an Apnea Hypopnea Index (AHI) ≥10 or Central Apnea Index (CAI) ≥5~or~• Participants who previously demonstrated Central sleep Apnea (CSA), with a CAI≥5 on Continuous Positive Airway Pressure (CPAP) titration.~Exclusion Criteria:~* • Participants who are acutely ill, medically complicated or who are medically unstable.~  * Pregnancy (will confirm absence of pregnancy with a urine or serum pregnancy test in women of child bearing potential).~ * Participants in whom PAP therapy is otherwise medically contraindicated.~ * Participants who are unwilling to wear CPAP~ * Participants who are currently prescribed nocturnal oxygen use and are unable to forego oxygen during study nights.~ * Participants with previously diagnosed respiratory failure or respiratory insufficiency and who are known to have chronically elevated arterial carbon dioxide levels while awake (PaCO2 ≥ 45mmHg).~ * Participants who have had surgery of the upper airway, nose, sinus, or middle ear within the previous 90 days.~ * Participants with untreated, non- Obstructive Sleep Apnea (OSA)/CSA sleep disorders, including but not limited to; insomnia, periodic limb movement syndrome, or restless legs syndrome (PLM Arousal Index \> 15).~ * Participants who are unwilling to participate in the study.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Respironics BiPAP autoSV2, Then Respironics BiPAP autoSV3 (Type: ACTIVE_COMPARATOR): Participants will be randomized to receive Respironics BiPAP autoSV2 first and Respironics BiPAP autoSV3 second.
- Respironics BiPAP autoSV3, then Respironics BiPAP autoSV2 (Type: EXPERIMENTAL): Participants will be randomized to receive Respironics BiPAP autoSV3 first and Respironics BiPAP autoSV2.

Based on this trial design, predict the completion outcome and termination type (if applicable).